Edition:
United Kingdom

Xenon Pharmaceuticals Inc (XENE.OQ)

XENE.OQ on NASDAQ Stock Exchange Global Market

3.72USD
5:06pm GMT
Change (% chg)

$0.03 (+0.68%)
Prev Close
$3.70
Open
$3.75
Day's High
$3.75
Day's Low
$3.72
Volume
591
Avg. Vol
11,460
52-wk High
$9.90
52-wk Low
$2.15

Chart for

About

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $54.00
Shares Outstanding(Mil.): 18.00
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Xenon Advances Second Proprietary Epilepsy Product Into Clinic With Initiation Of Xen901 Phase 1 Clinical Trial

* XENON PHARMACEUTICALS ADVANCES SECOND PROPRIETARY EPILEPSY PRODUCT INTO THE CLINIC WITH INITIATION OF XEN901 PHASE 1 CLINICAL TRIAL Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

20 Feb 2018

BRIEF-Xenon Pharmaceuticals Expects To Have Ongoing XEN1101 Phase 1 Clinical Trial Completed By Mid-Year

* XENON PHARMACEUTICALS INC - EXPECT TO HAVE ONGOING XEN1101 PHASE 1 CLINICAL TRIAL COMPLETED BY MID-YEAR

08 Jan 2018

BRIEF-Xenon Pharma Says Entered Into Loan And Security Agreement With Silicon Valley Bank

* XENON PHARMACEUTICALS- ON DEC 18, CO, UNIT ENTERED INTO LOAN AND SECURITY AGREEMENT WITH SILICON VALLEY BANK - SEC FILING

18 Dec 2017

BRIEF-Xenon Pharmaceuticals reports Q3 loss per share $0.43

* Xenon Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

07 Nov 2017

BRIEF-Xenon Pharma announces initiation of XEN1101 phase 1 clinical trial

* Xenon Pharmaceuticals announces initiation of XEN1101 phase 1 clinical trial

17 Oct 2017

Earnings vs. Estimates